Why Pennsylvania residents are pursuing GLP-1 claims
Across Pennsylvania, doctors prescribed Ozempic, Wegovy, Mounjaro, and Zepbound aggressively over the past several years for diabetes and weight loss. Many patients trusted those prescriptions only to develop life-changing injuries: gastroparesis, pancreatitis, intestinal obstruction, gallbladder disease, sudden vision loss, or worse.
Lawsuits allege that Novo Nordisk and Eli Lilly knew of these risks and failed to warn patients and prescribing physicians. The federal cases are consolidated as MDL 3094 in the Eastern District of Pennsylvania — putting Pennsylvania residents geographically and procedurally close to the action.
Injuries that may qualify
If you live in or near Pennsylvania and were prescribed a GLP-1 drug, you may qualify if you were diagnosed with gastroparesis (stomach paralysis), severe or recurrent pancreatitis, intestinal obstruction or ileus, gallbladder disease requiring surgery, aspiration pneumonia during anesthesia, NAION (sudden vision loss), or medullary thyroid cancer.
Statute of limitations in Pennsylvania
Pennsylvania generally imposes a two-year statute of limitations on personal-injury and product-liability claims, measured from when the injury was — or reasonably should have been — discovered. Once that window closes, your claim is permanently barred. Do not wait.
Next steps for Pennsylvania residents
Complete the case-review form on this page or call our intake line. A licensed attorney reviews every submission. If your case qualifies, we work with experienced mass tort co-counsel on a contingency-fee basis — you pay nothing unless your case results in a recovery.